

PERFORMANCE IN DELIVERING CLINICAL RESEARCH (Q2, 2013/14)

Research Ethics Committee Reference Number	Name of Trial	Target number of patients	Date agreed to recruit target number of patients	Trial status	Target met within the agreed time?
10/H0504/57	The safety & efficacy of AZD4547 in FGFR1 amplified breast cancer	7	31/03/2013	Closed - Follow Up Complete	Y
10/H0605/59	Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Two Year Study to Evaluate the Effect of Subcutaneous RO4909832 on Cognition and Function in Prodromal Alzheimer's Disease (WN25203)	6	01/09/2013	Closed - In Follow Up	Y
10/H0713/35	Post-operative delirium	6	01/06/2014	Open	Y
10/H1306/5	Phase III Open, Multicentre Study to Investigate the Safety and Efficacy of BPL's High Purity FACTOR X in the Treatment of Factor X Deficient Subjects Undergoing Surgery	1	31/12/2012	Closed - In Follow Up	Y
11/AL/0322	Phase 2 Placebocontrolled Doubleblind Trial of Dasatinib Added to Gemcitabine for Subjects with Locallyadvanced Pancreatic Cancer (OTSUKA)	2	30/10/2012	Closed - In Follow Up	Y
11/LO/0190	JVBA - Docetaxel and Ramucirumab for treating lung cancer	8	15/12/2012	Closed - In Follow Up	Y
11/LO/0449	Axitinib plus BSC v Placebo plus BSC in Advanced HCC Patients	2	30/06/2012	Closed - In Follow Up	Y
11/LO/0537	A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With Secondary Progressive Multiple Sclerosis	20	29/03/2013	Closed - In Follow Up	Y
11/LO/1164	A randomized, open-label, multicenter trial to determine safety and efficacy of Eculizumab in the prevention of Antibody Mediated Rejection (AMR) in living donor kidney transplant recipients requiring desensitization therapy	2	30/06/2013	Open	Y
11/LO/1415	Efficacy of OXN PR in severe Parkinson's disease associated pain (OXN2504)	4	02/06/2013	Closed - Follow Up Complete	Y
11/LO/1502	A Phase 3, Randomized, Double-Blinded, Placebo Controlled 3 arm Study of SAR302503 in Patients with Intermediate-2 or High Risk Primary (PMF), Post Polycythemia Vera (post PV-MF), or Post-Essential Thrombocythemia Myelofibrosis (post ET-MF)	2	09/12/2015	Closed - In Follow Up	Y
11/LO/1503	ARD12042 - A Randomized Phase II, Open-Label study of the Efficacy and Safety of Orally Administered SAR302503 in patients with polycythemia vera (PV) or essential thrombocythemia (ET) who are resistant or intolerant to hydroxyurea	2	12/03/2015	Closed - In Follow Up	Y
11/LO/1661	Electroanatomical Mapping using Rhythmia System and Catheter	6	01/05/2013	Closed - Follow Up Complete	Y
11/LO/2042	A Phase 2 open label biomarker study of angiotensin II type 2 receptor antagonist EMA401 for the treatment of pain in patients with chemotherapy-induced peripheral neuropathy	24	30/09/2013	Open	Y
11/NW/0298	A multicenter, Phase III, open-label, randomized study in previously untreated patients with advanced indolent non-Hodgkin's Lymphoma comparing GA101 (Ro5072759)/chemotherapy and rituximab/chemotherapy and GA101 or rituximab maintenance	2	28/02/2022	Open	Y

11/NW/0822	An Open-Label, Multicenter, Multinational Study to Assess the Effect of Long-Term Prolonged-Release Fampridine (BIIB041) 10 mg Twice Daily on Quality of Life as Reported by Subjects with Multiple Sclerosis (Enable)	15	01/09/2013	Closed - Follow Up Complete	Y
11/SC/0372	ChemoCentryx CL005_140 Study	2	01/07/2013	Closed - Follow Up Complete	Y
11/SC/0454	A phase IIIb parallel group, open label study of pegylated interferon alfa2a monotherapy (PEGIFN, Ro 258310) compared to untreated control in children with HBeAg positive chronic hepatitis B.	2	01/11/2014	Open	Y
11/SC/0499	An open-label multicenter, expanded access study of INC424 for patients with Primary Myelofibrosis (PMF), or post polycythemia myelofibrosis (PPV MF) or post-essential thrombocythemia myelofibrosis (PET-MF)	1	31/08/2013	Closed - In Follow Up	Y
12/LO/1597	SAPPHIRE - II: A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 Co-administered with Ribavirin (RBV) in Treatment-Experienced Adults?	5	01/04/2013	Closed - In Follow Up	Y
12/LO/1598	TURQUOISE - II: M13-099 Turquoise II cirrhotic study; A Randomized, Open-Label Study to Evaluate the Safety and Efficacy of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 Co-administered with Ribavirin (RBV) in Adults?	4	31/03/2013	Closed - In Follow Up	Y
12/NE/0266	A phase 3 multicenter, randomised, double-blind, placebo-controlled study to investigate the efficacy and safety of GS-7977 + Ribavirin for 12 weeks in treatment naive and treatment experienced subjects with chronic genotype 2 or 3 HCV infection	5	01/09/2012	Closed - In Follow Up	Y
12/NE/0342	A Study to Evaluate the Efficacy and Safety of GFT505 once daily on Steatohepatitis in Patients with NonAlcoholic Steatohepatitis (NASH).A Multicentre, Randomized, Double Blind, PlaceboControlled study, with an?	6	01/02/2013	Closed - Follow Up Complete	Y
12/NW/0137	A randomised, doubleblind, multicentre, Phase III study of everolimus (RAD001) plus best supportive care versus placebo plus best supportive care in the treatment of patients with advanced NET of GI or lung origin RADIANT-4	5	03/11/2017	Open	Y
12/SC/0031	A Phase 3 Evaluation of BMS-790052 in Combination with Peg-Interferon Alfa-2a and Ribavirin in Treatment-Naive Subjects with Chronic Hepatitis C Genotype 4n (v1) - Clinical Protocol AI444042	2	30/04/2014	Closed - In Follow Up	Y
12/YH/0178	A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of GS-1101 (CAL-101) in Combination with Rituximab for Previously Treated Chronic Lymphocytic Leukemia	5	01/05/2013	Closed - In Follow Up	Y
GTAC185	A Randomized, Double-blind, Phase 3 Efficacy Trial of PROSTVAC-V/F ? GM-CSF in Men With Asymptomatic or Minimally Symptomatic Metastatic, Castrate-Resistant Prostate Cancer	5	05/12/2013	Open	Y
12/LO/0355	192024-041D - A Multicenter, Paired-eye Comparison, Dose-escalation, Single Dose, 24-Month Study of Safety and Efficacy of Bimatoprost Preservative Free Intracameral Drug Delivery System (Bimatoprost PF IC DDS) in Patients With Open-Angle Glaucoma	6	31/12/2012	Withdrawn	Y
13/LO/0552	SinuSys Patency of Maxillary Sinus Ostia Study	6	01/06/2013	Closed - In Follow Up	Y
10/H0711/11	Multicenter, Double-blind, Randomized, Parallel-group, Monotherapy, Active control Study to Determine the Efficacy and safety of Daclizumab High Yield Process (DAC HYP) versus Avonex? (Interferon ?-1a) in patients with?	6	01/11/2011	Closed - In Follow Up	Y

12/LO/1748	A Phase 3, Multicenter, Randomized, Open-Label Study to Investigate the Efficacy and Safety of Sofosbuvir/GS-5885 Fixed Dose Combination + Ribavirin for 12 and 24 weeks in Treatment-Na?ve Subjects with Chronic Genotype 1 HCV Infection	5	01/04/2014	Closed - In Follow Up	Y
10/H0504/47	A multicentre, randomised, double-blind, placebocontrolled, parallel-group phase II study on the efficacy and safety of DEB025 combined with peg-IFN alfa-2a and ribavirin in chronic hepatitis C genotype 1 patients who are previous?	4	17/12/2010	Closed - Follow Up Complete	Y
10/H0715/57	A Multinational Phase 3, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of Oral MDV3100 in Chemotherapy-Naive Patients With Progressive Metastatic Prostate Cancer Who Have Failed Androgen Deprivation Therapy	5	01/11/2011	Closed - In Follow Up	Y
11/H0706/5	A Phase III, randomized, double-blind, placebo-controlled study to investigate the efficacy, safety and tolerability of TMC435 vs Placebo as part of a treatment regimen including peginterferon alfa-2a and ribavirin in hepatitis C?	5	01/08/2011	Closed - Follow Up Complete	Y
11/H0706/6	A Phase III, randomized, double-blind, placebo-controlled study to investigate the efficacy, safety and tolerability of TMC435 vs Placebo as part of a treatment regimen including peginterferon alfa-2a and ribavirin in hepatitis C?	6	01/08/2011	Closed - Follow Up Complete	Y
11/LO/0278	A randomized, open-label, multicenter study to evaluate the sustained virological response of the HCV protease inhibitor Danoprevir boosted with low dose ritonavir (Danoprevir / r) and Copegus? in combination with the?	5	01/08/2011	Closed - Follow Up Complete	Y
11/LO/1739	NV27779 - A phase II randomized, double-blind multicenter active-controlled parallel group study to evaluate the sustained virological response of the HCV polymerase inhibitor pro-drug RO5024048 in combination with?	5	01/09/2013	Closed - In Follow Up	Y
11/SC/0161	A randomized, double-blind, placebo controlled trial of the efficacy and safety of DEB025/Alisporivir in combination with standard of care in hepatitis C genotype 1 treatment na?ve patients	5	01/11/2011	Closed - In Follow Up	Y
12/EE/0499	A Phase II Randomized, Dose Ranging, Clinical Trial to Evaluate the Safety, Tolerability, and Efficacy of Different Doses of MK-5172 When Administered Concomitantly with Peginterferon alfa-2b and Ribavirin?	5	No Date Agreed With Sponsor	Closed - In Follow Up	Y
13/LO/0006	A Phase 3, Open-label Study to Investigate the Efficacy and Safety of Sofosbuvir plus Ribavirin in Chronic Genotype 1, 2, 3 and 4 Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV) Co-infected Subjects	5	31/07/2013	Closed - In Follow Up	Y
10/H0707/93	An open-label positron emission tomography study to investigate and quantify brain and tumour penetration of [11C]lapatinib in subjects with HER2-overexpressing breast cancer	10	01/09/2012	Closed - Follow Up Complete	Y
13/SC/0360	A Phase 3 Blinded Randomized Study of Peginterferon Lambda-1a and Ribavirin Compared to Peginterferon Alfa 2a and Ribavirin, Each Administered with Telaprevir in Subjects with?	4	21/10/2013	Closed - In Follow Up	Y
11/EM/0305	A Phase 3 Multicentre, Randomised, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Ustekinumab in the Treatment of Adolescent Subjects with Moderate to Severe Plaque-type Psoriasis (CADMUS)	2	31/10/2013	Closed - In Follow Up	N/A
11/H0707/8	A Randomized, Double-Blind, Placebo-Controlled Multi-center Phase II Study to Evaluate the Safety and Efficacy and Dose Response of 28 Days of Once-Daily Dosing of the Oral Motilin Receptor Agonist GSK962040, in Type I and II Diabetic	2	No Date Agreed With Sponsor	Closed - Follow Up Complete	N/A
11/LO/1040	A long-term monitoring study to evaluate the persistence of direct acting antiviral (DAA) treatment-resistant mutations or the durability of sustained virological response (SVR) in patients treated with DAA-containing regimens for chronic?	2	No Date Agreed With Sponsor	Open	N/A

12/EE/0176	RANDOMISED, PHASE IV, PLACEBO-CONTROLLED, COMPARATIVE STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAPERING METHOTREXATE (MTX) DOSAGE VERSUS MAINTAINING THE DOSAGE IN PATIENTS WITH SEVERE ACTIVE RHEUMATOID ARTHRITIS (RA) WHO HAVE DEMONSTRATED?	5	01/01/2014	Open	N/A
12/LO/1173	An Open-Label Phase I/II Study of GSK2110183 in Combination with Carboplatin and Paclitaxel in Subjects with Platinum-Resistant Ovarian Cancer	12	31/08/2014	Open	N/A
12/LO/1358	Randomized, Double-Blind, Phase 3 Study of TAS-102 Plus Best Supportive Care (BSC) Versus Placebo Plus BSC In Patients With Metastatic Colorectal Cancer Refractory To Standard Chemotherapies	5	10/10/2012	Withdrawn	N/A
12/NW/0251	A multi-centre, stratified, open, randomized, comparator-controlled, parallel-group phase III study comparing treatment with 177Lu-DOTA0-Tyr3-Octreotate to Octreotide LAR in patients with inoperable, progressive, somatostatin receptor?	5	01/06/2015	Open	N/A
12/NW/0431	A Multi-Centre, Open-Label, Adaptive, Randomised Study of Palifosfamide-tris, a Novel DNA Crosslinker, in Combination with Carboplatin and Etoposide (PaCE) Chemotherapy versus Carboplatin and Etoposide (CE) Alone in Chemotherapy?	5	01/04/2014	Open	N/A
12/NW/0555	Randomized phase II study of BEZ235 or everolimus in advanced pancreatic neuroendocrine tumors	2	15/04/2015	Open	N/A
12/SS/0045	A phase 2, multicentre, randomised, double-blind, placebo-controlled trial of AMG 479 or placebo in combination with Gemcitabine as first-line therapy for locally advanced unresectable adenocarcinoma of the pancreas		No Date Agreed With Sponsor	Open	N/A
12/WS/0180	A multicenter, two stage, phase II study, evaluating the efficacy of oral BEZ235 plus best supportive care (BSC) versus placebo plus BSC in the treatment of patients with advanced pancreatic neuroendocrine?	2	12/03/2015	Open	N/A
13/LO/0223	A combined retrospective and prospective post marketing surveillance study in patients using Temperature controlled Laminar Airflow (TLA)	400	No Date Agreed With Sponsor	Suspended	N/A
12/EE/0055	Research Project in Association with Protocol WN25 203 "CSF sample retention for biomarker assay development"		No Date Agreed With Sponsor	Open	N/A
12/LO/1320	Aneurysm Treatment using the HeliFX Aortic Securement System Global Registry	5	26/11/2013	Open	N/A
11/LO/1023	A 12Month, Multicentre, Randomised, Parallel Group Study to Compare the Efficacy and Safety of Ozurdex Versus Lucentis in Patients with Branch Retinal Vein Occlusion	10	31/10/2013	Open	N/A
11/SC/0358	An Open-Label Re-treatment Study with Peg-Interferon Alfa-2a, Ribavirin and BMS-790052 With or Without BMS-650032 for Subjects With Chronic Hepatitis C (Clinical Protocol A1444026)	1	28/02/2014	In set up	N/A
12/LO/0984	A RANDOMIZED, OPENLABEL, PHASE 2 STUDY OF THE IDO INHIBITOR INCB024360 (I) VERSUS TAMOXIFEN (C) FOR SUBJECTS WITH BIOCHEMICALRECURRENTONLY EPITHELIAL OVARIAN CANCER, PRIMARY PERITONEAL CARCINOMA, OR FALLOPIAN TUBE?	5	31/07/2014	Open	N/A
12/LO/1343	A Phase 1, Randomized, Double-blind, Placebo-controlled Study Evaluating CNTO 3157 in Healthy Normal and Asthmatic Subjects Inoculated with Human Rhinovirus Type 16	2	09/09/2014	Open	N/A
12/LO/1823	A Randomized, Double-blind Phase 3B Study to Evaluate the Safety and Efficacy of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate Versus Ritonavir-Boosted Atazanavir Plus Emtricitabine/Tenofovir Disoproxil ?	10	19/12/2013	Open	N/A

12/LO/1861	A Randomised, Open-label, Active-controlled, Multi-centre Study to Evaluate the Safety of Rivaroxaban and Vitamin K Antagonists in Subjects Undergoing Catheter Ablation for Atrial Fibrillation	8	19/11/2013	Open	N/A
12/LO/1981	A Randomized, Multicenter, Open-Label Phase III Study To Evaluate The Efficacy And Safety Of Trastuzumab Emtansine Versus Trastuzumab As Adjuvant Therapy For Patients With Her2-Positive Primary Breast Cancer Who Have Residual Tumor?	3	01/03/2016	Open	N/A
12/NW/0629	A Phase 3 Randomized, Open-Label Study of Ponatinib versus Imatinib in Adult Patients with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase.	5	01/06/2014	Suspended	N/A
12/NW/0711	Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, 12-Month Trial of Leuco-methylthionium bis(hydromethanesulfonate) in Subjects with Mild to Moderate Alzheimer's Disease	10	01/01/2014	Open	N/A
12/SC/0538	A Double-Blind, Placebo-Controlled, Randomized, Parallel Group, 12-Month Safety and Efficacy Trial of Leuco-methylthionium bis(hydromethanesulfonate) in Subjects with Behavioral Variant Frontotemporal Dementia (bvFTD)	4	01/01/2014	Open	N/A
12/SS/0007	A randomised Phase 2 Placebo-Controlled Study of LY2495655 in Patients with Advanced or Metastatic Pancreatic Cancer Receiving Chemotherapy	4	30/01/2014	Open	N/A
12/WS/0184	AntiCCR4 Monoclonal Antibody KW0761 in patients with ATL	3	15/06/2014	Open	N/A
13/NW/0171	A Phase 2b, Randomized, Double-blind, Placebo-controlled Study Investigating the Efficacy and Safety of Inhaled CVT-301 (Levodopa Inhalation Powder) in Parkinson's Disease Patients With Motor Response Fluctuations (OFF Phenomena)	5	01/02/2014	In set up	N/A
13/WA/0064	A performance evaluation study of Urosens mcm5 Elisa test in the diagnosis of bladder cancer in patients presenting with haematuria and lower urinary tract symptoms with suspicion of malignancy	250	01/11/2013	Open	N/A
13/SC/0146	A phase III, randomised, open label, activecontrolled study of an interferonfree regimen of BI 207127 in combination with Faldaprevir and Ribavirin compared to Telaprevir in combination with pegylated interferona and ribavirin in treatment?	3	30/03/2016	In set up	N/A
NULL	A Randomized, Double-Blind, Multi-Center Phase 3 Study of ADI-PEG 20 Plus Best Supportive Care (BSC) Versus Placebo Plus BSC in Subjects With Advanced Hepatocellular Carcinoma (HCC) Who Have Failed Prior Systemic Therapy	3	01/12/2013	Open	N/A
12/LO/1188	A Study of HSP90 Inhibitor AT13387 Alone or in Combination with Abiraterone Acetate in the Treatment of CastrationResistant Prostate Cancer (CRPC) no Longer Responding to Abiraterone	2	30/09/2014	In set up	N/A
13/LO/0097	A phase 2b dose-ranging, randomized, double-blind, placebo controlled trial evaluating the safety and efficacy of GS-6624, a monoclonal antibody against Lysyl oxidase like molecular 2 (LOXL2) in subjects?	5	No Date Agreed With Sponsor	Open	N/A
13/LO/0129	A Phase 4 Cross-Sectional Study of Bone Mineral Density in HIV-1 Infected Subjects	6	No Date Agreed With Sponsor	In set up	N/A
13/LO/0535	A Randomized Controlled Phase 3 Study of Oral Pacritinib versus Best Available Therapy in Patients with Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis	3	31/12/2013	Open	N/A
13/NE/0177	A phase II, randomised, double-blind, placebo-controlled study to evaluate LUM001, an apical sodium-dependent bile acid transporter inhibitor (ASBTi), in combination with ursodeoxycholic acid (UDCA) in patients with primary biliary cirrhosis	3	01/03/2014	Open	N/A

13/SC/0174	A phase 2b dose-ranging, randomized, double-blind, placebo-controlled trial evaluating the safety and efficacy of GS-6624, a monoclonal antibody against lysyl oxidase like molecular 2 (LOXL2) in subjects with Primary Sclerosing Cholangitis (PSC)	5	01/12/2013	Open	N/A
13/SC/0249	A phase 2b dose-ranging, randomized, double-blind, placebo controlled trial evaluating the safety and efficacy of GS-6624, a monoclonal antibody against Lysyl oxidase like molecular 2?	5	No Date Agreed With Sponsor	Open	N/A
09/H0406/106	Ofatumumab versus Rituximab Salvage Chemoimmunotherapy followed by ASCT in Relapsed or Refractory DLBCL	5	30/09/2012	Closed - Follow Up Complete	N
10/H0711/6	Cardiovascular outcomes to evaluate the potential of aleglitazar to reduce cardiovascular risk in patients with a recent acute coronary syndrome (ACS) event & type 2 diabetes (T2D)	60	30/05/2011	Closed - In Follow Up	N
10/H1002/27	Denosumab as Adjuvant Treatment for Early Stage Breast Cancer (DCARE)	20	01/11/2012	Closed - In Follow Up	N
11/EE/0210	A randomised double blind placebo-controlled phase 2 study to evaluate the safety and efficacy of CCX168 in Subjects with anti-neutrophil cytoplasmic antibody (ANCA)- associated renal vasculitis on background cyclophosphamide treatment	2	30/06/2012	Suspended	N
11/H0502/12	An open label, phase II trial of BIBW 2992 (afatinib) in patients with metastatic HER2overexpressing breast cancer failing HER2targeted treatment in the neoadjuvant and/or adjuvant treatment setting	20	30/04/2012	Open	N
11/LO/0448	A randomized, double-blind, placebo-controlled, multiple dose, exploratory proof of concept study to assess the safety, tolerability, efficacy, pharmacodynamics and pharmacokinetics of QAX576 in progressive idiopathic pulmonary fibrosis	4	31/08/2012	Closed - Follow Up Complete	N
11/NW/0690	Bardoxolone Methyl Evaluation in Patients with Chronic Kidney Disease and Type 2 Diabetes: the Occurrence of Renal Events (BEACON)	8	31/07/2012	Closed - In Follow Up	N
11/WM/0279	Neural Cardiac Therapy for Heart Failure (NECTAR-HF) Research Study	10	31/12/2013	Closed - In Follow Up	N
12/EE/0005	A multicentre, double blind, randomised controlled Clinical Investigation to validate the EPS1 device as a treatment for stroke induced dysphagia. A Study of Swallowing Treatment using Electrical Pharyngeal Stimulation (STEPS Study)	6	01/01/2013	Open	N
12/LO/0009	RAFFAELLO Ranolazine in AF following an electrical cardioversion	10	01/08/2012	Closed - Follow Up Complete	N
12/LO/0098	A randomized, double blind, placebo controlled, multiple dose study to evaluate the safety, tolerability, and efficacy of intravenous administration of secukinumab (AIN457) in patients with asthma not adequately controlled?	6	01/08/2013	Open	N
12/LO/0268	Open-Label, Phase 3b Study to Determine Efficacy and Safety of Telaprevir, Pegylated-Interferon-alfa-2a and Ribavirin in Hepatitis C Virus Treatment-Naïve and Treatment-Experienced Subjects with Genotype 1 Chronic Hepatitis C?	4	01/03/2013	Closed - In Follow Up	N
12/LO/0410	A Double-Blind, Randomized, Parallel Group, Multi-Centre Study to Evaluate the Efficacy and Safety of Mirabegron Compared to Solifenacin in Subjects with Overactive Bladder (OAB) Treated with Antimuscarinics and?	12	30/11/2012	Closed - Follow Up Complete	N

12/SC/0025	A 24month, phase IIIb, openlabel, randomized, activecontrolled, 3arm, multicenter study assessing the efficacy and safety of an individualized, stabilization criteria driven PRN dosing regimen with 0.5mg ranibizumab intravitreal?	7	28/02/2013	Closed - Follow Up Complete	N
12/SC/0024	A 24month, phase IIIb, openlabel, single arm, multicenter study assessing the efficacy and safety of an individualized, stabilization criteriadriven PRN dosing regimen with 0.5mg ranibizumab intravitreal injections applied?	5	31/07/2012	Closed - In Follow Up	N
12/SC/0042	A Phase III, randomized, double-blind trial to evaluate the efficacy, safety and tolerability of TMC435 vs. telaprevir, both in combination with PegIFN?-2a and ribavirin, in chronic hepatitis C genotype-1 infected subjects who?	5	30/09/2012	Closed - In Follow Up	N
12/SC/0435	Efficacy and safety of 3 doses of S 38093 (2, 5 and 20 mg/day) versus placebo, in co-administration with donepezil (10mg/day) in patients with moderate Alzheimer's Disease	10	01/07/2013	Open	N
12/YH/0179	A Companion Trial to Study GS-US-312-0116: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of GS-1101 (CAL-101) in Combination with Rituximab as Therapy for Patients with Previously?	5	01/05/2013	Open	N
12/YH/0318	A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of GS-1101 (CAL-101) in Combination with Bendamustine and Rituximab for Previously Treated Chronic Lymphocytic Leukemia	5	01/06/2013	Open	N
10/H0713/88	A Pivotal Phase 2 Trial of Ponatinib (AP24534) in Patients with Refractory Chronic Myeloid Leukemia and Ph+ Acute Lymphoblastic Leukemia.	350	30/09/2011	Closed - Follow Up Complete	N
10/H1211/20	LEADER, liraglutide cardiovascular outcome study in type 2 diabetes	20	01/03/2012	Closed - In Follow Up	N
12/LO/0486	An Ascending Single Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics/Pharmacodynamics of PF-05280602. A Recombinant Factor VIII Variant (813), in adult Hemophilia A and B Subjects with or without inhibitors	1	01/03/2013	In set up	N
13/LO/0425	A Randomized, Double-Blind, Controlled Study to Evaluate the Efficacy and Safety of the Combination of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and BT-333 With and Without Ribavirin (RBV) in Treatment-Na?ve?	5	01/05/2013	Closed - In Follow Up	N
11/LO/1220	A Phase III open label trial of TMC435 in combination with peginterferon alfa2a and ribavirin for HCV genotype1 infected subjects who participated in the placebo group of a Phase II/III TMC435 study (C201, C205, C206, C208, C216 or HPC3007)?	2	30/09/2013	In set up	N
12/NW/0682	A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate Safety, Tolerability and Efficacy of AMG 145 on LDL-C in Subjects with Heterozygous Familial Hypercholesterolemia	8	01/07/2013	Closed - Follow Up Complete	N
08/H0606/125	TITRe 2: reducing transfusion after cardiac surgery (version 2.0)	400	13/02/2013	Closed - Follow Up Complete	N
09/H0707/95	A multicenter, double-blind, placebo-controlled Phase 3 study to demonstrate the efficacy and safety of ACT-293987 in patients with pulmonary arterial hypertension - Griphon2	5	30/06/2013	Closed - Follow Up Complete	N
10/H0703/79	Catheter Ablation Versus Antiarrhythmic Drug Therapy for Atrial Fibrillation Trial - CABANA Trial	21	23/11/2011	Closed - In Follow Up	N
12/LO/0174	A multi-center parallel group double blind placebo controlled single and multiple dose escalation study to assess the safety and tolerability and the pharmacokinetic properties of SAR228810?	5	No Date Agreed With Sponsor	Closed - In Follow Up	N

12/LO/1156	A Phase III , Randomised, Double-blind , Controlled Study of Cabozantinib (XL184) vs Prednisone in Metastatic Castration-resistant Prostate Cancer Patients who have Received Prior Docetaxel?	2	No Date Agreed With Sponsor	Closed - In Follow Up	N
12/SC/0540	A phase III, Randomised, Partially Double-Blind and Placebo-Controlled Study of BI 207127 in combination with Faldaprevir and Ribavirin in Treatment-Na?ve Patients with Chronic Genoptype 1 HCV Infection	3	No Date Agreed With Sponsor	Closed - In Follow Up	N
13/LO/0206	A phase 3 evaluation of Daclatasvir in combination with Peginterferon Lambda-1a and Ribavirin (RBV) or Telaprevir in Combination with Peginterferon Alfa-2a and RBV in Patients with?	4	01/11/2013	Closed - In Follow Up	N